TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33896710

Group type: EXPERIMENTAL
Intervention: Biparametric magnetic resonance imaging as a screening tool for prostate cancer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 33897480

Group type: EXPERIMENTAL
Intervention: Computerized Adaptive Tests (CAT) of Depression and Suicidal Ideation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Traditional ratings (Hamilton Depression Rating Scale, Beck Depression Inventory, Beck Scale for Suicidal Ideation)
Number of subjects: 20
Study: 33897536

Group type: EXPERIMENTAL
Intervention: Paternal bonding measures; specific intervention details not available
Number of subjects: 0
Study: 33897579

Group type: EXPERIMENTAL
Intervention: Virtual Reality intervention for motor and cognitive rehabilitation, details on dosage and duration not available.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified, details not available.
Number of subjects: 0
Study: 33897593

Group type: EXPERIMENTAL
Intervention: Intensive rehabilitation
Number of subjects: 0
Study: 33897615

Group type: EXPERIMENTAL
Intervention: Levoketoconazole
Number of subjects: 94
Study: 33897775

Group type: EXPERIMENTAL
Intervention: Neural oscillations measured 2 hours before surgery (specifically spectral power density of resting-state beta and gamma band oscillations at the frontocentral region)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Machine learning techniques predicting acute postoperative pain based on neural oscillations
Number of subjects: 0
Study: 33898065

Group type: EXPERIMENTAL
Intervention: Oral anticoagulant agents (OACs), including vitamin K antagonists (VKAs) and direct OACs (DOACs)
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Oral anticoagulant agents (OACs)
Number of subjects: 2000
Study: 33898536

Group type: EXPERIMENTAL
Intervention: Bioimpedance Spectroscopy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33898953

Group type: EXPERIMENTAL
Intervention: 3-monthly intramuscular depot medroxyprogesterone acetate (DMPA-IM)
Number of subjects: 7829

Group type: EXPERIMENTAL
Intervention: levonorgestrel (LNG) implant
Number of subjects: 7829

Group type: COMPARATOR
Intervention: copper intrauterine device (IUD)
Number of subjects: 7829
Study: 33898959

Group type: EXPERIMENTAL
Intervention: Aldafermin 0.3 mg
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Aldafermin 1 mg
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Aldafermin 3 mg
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Aldafermin 6 mg
Number of subjects: 238

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Aldafermin 1 mg (PSC)
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Aldafermin 3 mg (PSC)
Number of subjects: 238

Group type: COMPARATOR
Intervention: Placebo (PSC)
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Aldafermin
Number of subjects: 238
Study: 33898960

Group type: EXPERIMENTAL
Intervention: Low-Carb High-Fat diet (LCHF)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: 5:2 diet
Number of subjects: 74

Group type: COMPARATOR
Intervention: Standard of Care (SoC)
Number of subjects: 74
Study: 33899008

Group type: EXPERIMENTAL
Intervention: SPIN-CHAT Program (4-week videoconference-based group intervention, 3 sessions per week)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: SPIN-CHAT Program
Number of subjects: 172

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 172
Study: 33899152

Group type: EXPERIMENTAL
Intervention: Baricitinib 2 mg
Number of subjects: 1568

Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg
Number of subjects: 1568

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1568
Study: 33899504

Group type: EXPERIMENTAL
Intervention: Deep learning algorithm for murmur detection
Number of subjects: 962

Group type: EXPERIMENTAL
Intervention: Deep learning algorithm for murmur detection (omitting grade 1 murmurs)
Number of subjects: 962

Group type: EXPERIMENTAL
Intervention: Deep learning algorithm for detecting aortic stenosis
Number of subjects: 962

Group type: EXPERIMENTAL
Intervention: Deep learning algorithm for detecting mitral regurgitation
Number of subjects: 962
Study: 33899755

Group type: EXPERIMENTAL
Intervention: Emerging arboviruses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neuroinvasive arboviruses
Number of subjects: 0
Study: 33899978

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Waitlist (control)
Number of subjects: 250
Study: 33900000

Group type: EXPERIMENTAL
Intervention: MRI-enema
Number of subjects: 16

Group type: COMPARATOR
Intervention: WSCE
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Patient experience
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ileostomy reversal
Number of subjects: 16
Study: 33900099

Group type: EXPERIMENTAL
Intervention: Multidimensional Assessment of Parenting Scale (MAPS)
Number of subjects: 1790
Study: 33900278

Group type: EXPERIMENTAL
Intervention: Angiopoietin-like protein 3 inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33900485

Group type: EXPERIMENTAL
Intervention: Septic shock patients
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy young men (control group)
Number of subjects: 20
Study: 33901053

Group type: EXPERIMENTAL
Intervention: Living alone
Number of subjects: 3103

Group type: EXPERIMENTAL
Intervention: Living alone (Americas-based sample)
Number of subjects: 3103
Study: 33901188

Group type: EXPERIMENTAL
Intervention: Tissue specificity-aware TWAS (TSA-TWAS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cross-tissue TWAS (UTMOST)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single-tissue TWAS (PrediXcan)
Number of subjects: 0
Study: 33901280

Group type: EXPERIMENTAL
Intervention: Treatment of hyperthyroidism (restoration of euthyroidism)
Number of subjects: 51
Study: 33901438

Group type: COMPARATOR
Intervention: Having 2-3 chronic conditions vs 0-1
Number of subjects: 2438

Group type: COMPARATOR
Intervention: Having ≥4 chronic conditions vs 0-1
Number of subjects: 2438

Group type: COMPARATOR
Intervention: Presence of 2-3 chronic conditions
Number of subjects: 2438

Group type: COMPARATOR
Intervention: Presence of ≥4 chronic conditions
Number of subjects: 2438

Group type: COMPARATOR
Intervention: Triad of arthritis, depression, and anxiety
Number of subjects: 2438
Study: 33901551

Group type: EXPERIMENTAL
Intervention: Propofol at clinically administered doses using the Total Intravenous Anesthesia (TIVA/TCI) technique
Number of subjects: 27
Study: 33901660

Group type: EXPERIMENTAL
Intervention: Nail ultrasonography (NUSG)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: NUSG Index (NUSGI)
Number of subjects: 90

Group type: COMPARATOR
Intervention: NUSG
Number of subjects: 90
Study: 33902087

Group type: EXPERIMENTAL
Intervention: Adjunctive music during ketamine infusion
Number of subjects: 2

Group type: COMPARATOR
Intervention: Ketamine infusion without music
Number of subjects: 2
Study: 33902099

Group type: EXPERIMENTAL
Intervention: Telephone-based physical activity coaching intervention
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Sedentary behavior in the afternoon
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Sedentary behavior in the evening
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 54
Study: 33902320

Group type: EXPERIMENTAL
Intervention: Acute Daily Stress
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Daily Food Consumption
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Disordered Eating
Number of subjects: 0
Study: 33902450

Group type: EXPERIMENTAL
Intervention: Higher PpO2 (> 250 mmHg)
Number of subjects: 376

Group type: COMPARATOR
Intervention: Lower PpO2 (≤ 250 mmHg)
Number of subjects: 376
Study: 33902478

Group type: EXPERIMENTAL
Intervention: KCD score ≥ 20 years (KCD20)
Number of subjects: 0

Group type: COMPARATOR
Intervention: KCD20, eGFRstep, or eGFR < 60 ml/min/1.73 m²
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: KCD20 or eGFR < 60 ml/min/1.73 m²
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: KCD20
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: KCD score
Number of subjects: 0
Study: 33902556

Group type: COMPARATOR
Intervention: Higher plasma mitochondrial DNA (p-mtDNA) levels in participants with mild or moderate COPD compared to smokers without airflow obstruction and participants with severe COPD.
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Higher plasma mitochondrial DNA (p-mtDNA) levels in male participants with severe COPD.
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Baseline increased p-mtDNA levels in females with severe COPD.
Number of subjects: 700
Study: 33902599

Group type: EXPERIMENTAL
Intervention: 5 to 17 months age-group
Number of subjects: 14329
Study: 33903092

Group type: EXPERIMENTAL
Intervention: Positive APLA serology in COVID-19 patients
Number of subjects: 22

Group type: COMPARATOR
Intervention: Positive APLA serology in non-COVID-19 patients
Number of subjects: 22
Study: 33903114

Group type: EXPERIMENTAL
Intervention: External popPK model of TMP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: External popPK model of SMX
Number of subjects: 0

Group type: COMPARATOR
Intervention: POPS TMP model
Number of subjects: 0

Group type: COMPARATOR
Intervention: POPS SMX model
Number of subjects: 0
Study: 33903148

Group type: EXPERIMENTAL
Intervention: High-fat diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Western diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Choline-deficient high-fat diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Western diet supplemented with fructose and glucose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pemafibrate (PPARα agonist)
Number of subjects: 0
Study: 33903178

Group type: EXPERIMENTAL
Intervention: Coexisting intracranial stenosis ≥50% and carotid mean wall thickness (MWT) ≥1 mm
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Calcification
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Lipid-rich necrotic core (LRNC)
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Coexisting intracranial artery stenosis ≥50% and carotid MWT ≥1 mm
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Coexisting intracranial stenosis ≥50% with carotid MWT ≥1 mm (after adjustment)
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Calcification (after adjustment)
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Lipid-rich necrotic core (LRNC) (after adjustment)
Number of subjects: 351
Study: 33903179

Group type: EXPERIMENTAL
Intervention: Intravenous recombinant tissue plasminogen activator (r-tPA), median dose 0.88 (IQR 0.78-0.90) mg/kg
Number of subjects: 3810

Group type: COMPARATOR
Intervention: Urokinase (UK), median dose 1.71 (1.43-2.00)×10
Number of subjects: 3810

Group type: EXPERIMENTAL
Intervention: Both r-tPA and UK
Number of subjects: 3810
Study: 33903255

Group type: EXPERIMENTAL
Intervention: Higher education
Number of subjects: 4422

Group type: COMPARATOR
Intervention: Lower education
Number of subjects: 4422
Study: 33904646

Group type: EXPERIMENTAL
Intervention: Taxane chemotherapy (docetaxel or cabazitaxel)
Number of subjects: 0
Study: 33904819

Group type: EXPERIMENTAL
Intervention: Community-based computerized cognitive training (CCT) program, 10-week duration, 2-hour instructor-led group classes twice a week.
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 94
Study: 33904821

Group type: EXPERIMENTAL
Intervention: Self-reported computerized history taking (CHT) on a tablet
Number of subjects: 500
Study: 33904895

Group type: EXPERIMENTAL
Intervention: Lisocabtagene maraleucel (liso-cel)
Number of subjects: 0
Study: 33904996

Group type: EXPERIMENTAL
Intervention: Dietary patterns including 'starchy veggies, meats and alcohol pattern'
Number of subjects: 1255

Group type: EXPERIMENTAL
Intervention: Increasing intake of dietary proteins and total fats
Number of subjects: 1255

Group type: EXPERIMENTAL
Intervention: Dietary total fats
Number of subjects: 1255

Group type: EXPERIMENTAL
Intervention: Dietary saturated fats, omega-3 fats, and fiber
Number of subjects: 1255
Study: 33905010

Group type: EXPERIMENTAL
Intervention: Dye leak test (DLT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Air leak test (ALT)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Suture reinforcement of the anastomosis
Number of subjects: 40
Study: 33905264

Group type: EXPERIMENTAL
Intervention: Post-transplant cyclophosphamide (PTCy) with myeloablative or reduced-intensity conditioning
Number of subjects: 80

Group type: COMPARATOR
Intervention: Post-transplant cyclophosphamide (PTCy)
Number of subjects: 80
Study: 33905373

Group type: EXPERIMENTAL
Intervention: Reduction of β cell mass (50% mass reduction)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal glucose tolerance (post-NGT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Impaired glucose tolerance (post-IGT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diabetes mellitus (post-DM)
Number of subjects: 0
Study: 33905540

Group type: EXPERIMENTAL
Intervention: Drug therapies that reduce gastric acidity
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 analogue misoprostol
Number of subjects: 273

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 273
Study: 33905544

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study: 33906372

Group type: EXPERIMENTAL
Intervention: Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12) summary score
Number of subjects: 23291

Group type: EXPERIMENTAL
Intervention: KCCQ-12 summary score
Number of subjects: 23291
Study: 33906374

Group type: EXPERIMENTAL
Intervention: Clinical genetic testing for cardiomyopathy
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Positive family history and hypertrophic cardiomyopathy subtype
Number of subjects: 152
Study: 33906377

Group type: EXPERIMENTAL
Intervention: High salt (HS) treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacological uncoupling of the electron transport chain under normal salt
Number of subjects: 0
Study: 33906420

Group type: EXPERIMENTAL
Intervention: Thyrotropin, Free Triiodothyronine, and Free Thyroxine measurements
Number of subjects: 0
Study: 33906916

Group type: EXPERIMENTAL
Intervention: Insulin-Only iLet Bionic Pancreas
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bihormonal iLet Using Dasiglucagon
Number of subjects: 0
Study: 33906957

Group type: EXPERIMENTAL
Intervention: Diaphragmatic excursion velocity measured with dTDI at the end of SBT
Number of subjects: 100
Study: 33907136

Group type: EXPERIMENTAL
Intervention: Self-acupressure therapy at acupoints TE17 (Yifeng), TE21 (Ermen), SI19 (Tinggong), and GB2 (Tinghui)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Conventional Valsalva and Toynbee maneuvers
Number of subjects: 152
Study: 33907423

Group type: EXPERIMENTAL
Intervention: Accessorized pre-filled syringe (APFS)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Autoinjector (AI)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Both APFS and AI
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: APFS
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: AI
Number of subjects: 216
Study: 33907455

Group type: EXPERIMENTAL
Intervention: Dexamethasone group (0.5% ropivacaine plus 0.033% dexamethasone)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (0.5% ropivacaine alone)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Dexamethasone group
Number of subjects: 140
Study: 33907462

Group type: EXPERIMENTAL
Intervention: Suprainguinal fascia iliaca block (FIB)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Transmuscular quadratus lumborum block (QLB)
Number of subjects: 36
Study: 33908631

Group type: EXPERIMENTAL
Intervention: Corticosteroids and antibiotics
Number of subjects: 21

Group type: COMPARATOR
Intervention: Antibiotics alone
Number of subjects: 21
Study: 33909232

Group type: EXPERIMENTAL
Intervention: Selinexor 60 mg once weekly in combination with intravenous topotecan
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Selinexor 80 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Selinexor 60 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Treatment-related adverse events (TRAE)
Number of subjects: 14
Study: 33909449

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (BV) + doxorubicin, vinblastine, and dacarbazine (AVD) for four cycles
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (BV) + AVD
Number of subjects: 117
Study: 33909588

Group type: EXPERIMENTAL
Intervention: Support, monitoring, and reminder technology for mild dementia
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Television-based assistive integrated service
Number of subjects: 200

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 200
Study: 33909619

Group type: EXPERIMENTAL
Intervention: Isothermal Recombinase Polymerase Amplification (RPA) targeting Leishmania kinetoplast DNA with lateral flow (LF) immunochromatographic strip
Number of subjects: 118

Group type: COMPARATOR
Intervention: Standard of care routine diagnostic tests
Number of subjects: 118
Study: 33909934

Group type: EXPERIMENTAL
Intervention: Alpelisib + Fulvestrant
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard treatment (real-world cohort)
Number of subjects: 120
Study: 33910089

Group type: EXPERIMENTAL
Intervention: Ovarian tissue cryopreservation (OTC)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Testicular tissue cryopreservation (TTC)
Number of subjects: 75
Study: 33910154

Group type: EXPERIMENTAL
Intervention: Larger right than left frontal alpha power prior to drug treatment in female patients.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Higher central left alpha power relative to the right in female non-responders.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Lower theta activity at anterior cingulate cortex (ACC) in remitters.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Alpha asymmetry in women with MDD.
Number of subjects: 100
Study: 33910159

Group type: EXPERIMENTAL
Intervention: Insomnia Severity Index-3 (ISI-3)
Number of subjects: 3444

Group type: COMPARATOR
Intervention: 7-item ISI
Number of subjects: 3444
Study: 33910277

Group type: EXPERIMENTAL
Intervention: Neoadjuvant nivolumab plus ipilimumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neoadjuvant immune-chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nivolumab monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neoadjuvant immune checkpoint inhibitor monotherapy
Number of subjects: 0
Study: 33910334

Group type: EXPERIMENTAL
Intervention: Immunosuppressive therapy plus eltrombopag
Number of subjects: 416

Group type: COMPARATOR
Intervention: Immunosuppressive therapy alone
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Immunosuppressive therapy with or without eltrombopag
Number of subjects: 416

Group type: COMPARATOR
Intervention: Immunosuppressive therapy
Number of subjects: 416
Study: 33910942

Group type: EXPERIMENTAL
Intervention: Erenumab 140 mg
Number of subjects: 240
Study: 33910968

Group type: EXPERIMENTAL
Intervention: Exebacase (CF-301)
Number of subjects: 0

Group type: COMPARATOR
Intervention: S. aureus ATCC 29213
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enterococcus faecalis ATCC 29212
Number of subjects: 0
Study: 33911143

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Deferred revascularization
Number of subjects: 330
Study: 33912079

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 33912096

Group type: EXPERIMENTAL
Intervention: Olweus Bully/Victim Questionnaire-Revised version (OBVQ-R)
Number of subjects: 2775

Group type: COMPARATOR
Intervention: Comparison with the School Violence between Peers Questionnaire and the Internet Experiences Questionnaire
Number of subjects: 2775

Group type: EXPERIMENTAL
Intervention: Item Response Theory analysis
Number of subjects: 2775

Group type: EXPERIMENTAL
Intervention: Victimization scale
Number of subjects: 2775

Group type: EXPERIMENTAL
Intervention: Perpetration subscale
Number of subjects: 2775

Group type: EXPERIMENTAL
Intervention: Differential item functioning analysis by gender
Number of subjects: 2775
Study: 33912102

Group type: EXPERIMENTAL
Intervention: Resilience intervention for chronic pain
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 88
Study: 33912178

Group type: EXPERIMENTAL
Intervention: IL-35-secreting B (IL-35+B) cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IL-10-producing B (B10) cells
Number of subjects: 0
Study: 33912244

Group type: EXPERIMENTAL
Intervention: DA-first thrombectomy
Number of subjects: 1225

Group type: COMPARATOR
Intervention: SR-first thrombectomy
Number of subjects: 1225
Study: 33912273

Group type: EXPERIMENTAL
Intervention: Auricular Acupuncture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 33912450

Group type: EXPERIMENTAL
Intervention: Personalized dynamic physical activity intervention
Number of subjects: 57
Study: 33912461

Group type: EXPERIMENTAL
Intervention: Apatinib (250 mg orally per day) plus Camrelizumab (200 mg intravenously every three weeks)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Apatinib plus Camrelizumab
Number of subjects: 22
Study: 33912470

Group type: EXPERIMENTAL
Intervention: Sequential consolidation with pembrolizumab for four cycles followed by nab-paclitaxel for four cycles (P→A)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel followed by pembrolizumab (A→P)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Concurrent nab-paclitaxel and pembrolizumab for four cycles (AP)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Quality of life measured by FACT-L
Number of subjects: 20
Study: 33912524

Group type: EXPERIMENTAL
Intervention: Delayed Cord Clamping
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (Standard Cord Clamping)
Number of subjects: 0
Study: 33912651

Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 600
Study: 33912753

Group type: EXPERIMENTAL
Intervention: tolvaptan 60/30 mg daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: tolvaptan
Number of subjects: 0